Cargando…
Virotherapy: cancer gene therapy at last?
For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated expe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007754/ https://www.ncbi.nlm.nih.gov/pubmed/27635234 http://dx.doi.org/10.12688/f1000research.8211.1 |
_version_ | 1782451266500165632 |
---|---|
author | Bilsland, Alan E. Spiliopoulou, Pavlina Evans, T. R. Jeffry |
author_facet | Bilsland, Alan E. Spiliopoulou, Pavlina Evans, T. R. Jeffry |
author_sort | Bilsland, Alan E. |
collection | PubMed |
description | For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches. |
format | Online Article Text |
id | pubmed-5007754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-50077542016-09-14 Virotherapy: cancer gene therapy at last? Bilsland, Alan E. Spiliopoulou, Pavlina Evans, T. R. Jeffry F1000Res Review For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches. F1000Research 2016-08-30 /pmc/articles/PMC5007754/ /pubmed/27635234 http://dx.doi.org/10.12688/f1000research.8211.1 Text en Copyright: © 2016 Bilsland AE et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. |
spellingShingle | Review Bilsland, Alan E. Spiliopoulou, Pavlina Evans, T. R. Jeffry Virotherapy: cancer gene therapy at last? |
title | Virotherapy: cancer gene therapy at last? |
title_full | Virotherapy: cancer gene therapy at last? |
title_fullStr | Virotherapy: cancer gene therapy at last? |
title_full_unstemmed | Virotherapy: cancer gene therapy at last? |
title_short | Virotherapy: cancer gene therapy at last? |
title_sort | virotherapy: cancer gene therapy at last? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007754/ https://www.ncbi.nlm.nih.gov/pubmed/27635234 http://dx.doi.org/10.12688/f1000research.8211.1 |
work_keys_str_mv | AT bilslandalane virotherapycancergenetherapyatlast AT spiliopouloupavlina virotherapycancergenetherapyatlast AT evanstrjeffry virotherapycancergenetherapyatlast |